Background. Interferon alpha (IFN-α) can potently reduce human immunodeficiency virus type 1 (HIV-1) replication in tissue culture and animal models, but may also modulate residual viral reservoirs that persist despite suppressive antiretroviral combination therapy. However, mechanisms leading to viral reservoir reduction during IFN-α treatment are unclear.
Combined antiretroviral therapy (ART) effectively suppresses human immunodeficiency virus (HIV) replication, but does not eliminate CD4 T cells harboring dormant proviruses that are able to fuel rebound viremia when antiviral treatment is stopped [1, 2] . Several current efforts focus on manipulating human immune responses to reduce or eliminate these persisting reservoirs of virally infected cells. While most of these approaches focus on adaptive T-or B cell-mediated immune response through, for example, therapeutic vaccines or passive transfer of broadly neutralizing antibodies, very little is known about innate immune components that may lead to viral reservoir reduction.
Type I interferons are key cytokines that help to control viral infections [3] . Interferon alpha (IFN-α) can block HIV-1 replication by inducing or repressing the expression of a cascade of interferon-regulated genes and stimulating innate and adaptive immune cells [4] . IFN-α can reduce viral RNA in HIV type 1 (HIV-1)-infected humans and HIV/simian immunodeficiency virus (SIV)-infected animals [5] [6] [7] [8] , but may also exert deleterious effects during HIV-1 infection, especially during later stages of infection [4] . Specifically, IFN-α can accelerate apoptotic CD4 T-cell death and CD8 T-cell exhaustion, both in the SIV model [9, 10] and in chronic HIV-1 infection [11] .
Effects of IFN-α on the reservoir of latently HIV-1-infected CD4 T cells are less well understood. IFN-α may activate CD4 T-cellintrinsic viral restriction factors or viral sensing proteins that can selectively kill virally infected cells after disruption of viral latency [12] . In addition, IFN-α can activate natural killer (NK) cells, and increase their ability to recognize and kill infected cells [13, 14] . More recent evidence suggests that IFN-α can also have a role in protecting CD8 T cells from NK cell-mediated cytotoxicity by stimulating the upregulation of NK cell inhibitory receptors [15, 16] .
To study the impact of IFN-α treatment on the residual HIV-1 reservoir, we here conducted a detailed analysis of virological and immunological changes in a cohort of ART-treated HIV-1/ hepatitis C virus (HCV)-coinfected patients who received pegylated IFN-α (peg-IFN-α) and ribavirin (RBV) as treatment for HCV infection. We show that decreases in proviral HIV-1 DNA during treatment with IFN-α/RBV are associated with phenotypic and functional characteristics of NK cells, suggesting that IFN-α can reduce viral reservoirs through modulation of antiviral innate effector cells.
METHODS

Study Population
Peripheral blood mononuclear cell (PBMC) samples were obtained from HIV-1/HCV-coinfected patients from the Immunovirology Laboratory Cohort in Seville, Spain and the AIDS Study Group (GeSIDA) cohort in Madrid, Spain, who received suppressive combination ART and HCV treatment with IFN-α (180 μg/week of peg-IFN-α 2a [Roche] ) and RBV (600 mg twice daily for ≥75 kg body weight, 500 mg twice daily for <75 kg body weight). All patients had undetectable levels of HIV-1 RNA in commercial polymerase chain reaction (PCR) assays for all sample collection time points. Clinical and demographical characteristics of the HIV-1/ HCV-coinfected study patients are summarized in Table 1 . All patients gave written consent to donate samples for research purposes. The study was approved by the local institutional review boards and conducted in agreement with the Declaration of Helsinki.
Isolation of CD4 T Cells
CD4
+ T cells were isolated by immunomagnetic enrichment from 10 million PBMCs using an autoMACS Pro Separator (Miltenyi) according to the manufacturer's instructions. The purity of the CD4 + T cells was >95%, as assessed by flow cytometry (data not shown).
CD8 T-Cell and NK Cell Phenotype by Flow Cytometry
To analyze HIV- When necessary, the cells were preincubated for 10 minutes with 2 μL of Fc receptor (FcR) blocking antibodies. Afterward, the cells were fixed in a 2% paraformaldehyde solution, acquired on a 5-laser Fortessa flow cytometer (Becton Dickinson), and analyzed using FlowJo X software (Tree Star). Analysis and presentation of cell distributions were performed using GraphPad Prism software (version 7).
Assessment of Cell-Associated HIV-1 DNA
To extract cell lysates, isolated CD4 T-cell populations were digested as previously described [17] . Total HIV-1 DNA was amplified using digital droplet PCR (Bio-Rad) with primers and probes, as outlined previously [17] . Chromosomal DNA of the host gene RPP30 was simultaneously amplified to determine input cell numbers. PCR was performed using the following program: 95°C for 10 minutes, 45 cycles at 94°C for 30 seconds, and 60°C for 1 minute, followed by 98°C for 10 minutes. The droplets were subsequently read with a QX100 droplet reader and data were analyzed using QuantaSoft software (Bio-Rad).
Statistical Analysis
Data are expressed as individual data plots with horizontal bars reflecting the median and interquartile range. Bivariate comparisons between pre-and posttreatment were performed using Wilcoxon matched paired signed-rank tests or a 1-way analysis of variance and Bonferroni post hoc test. Generalized estimated equations (GEEs) were used to compute correlations across multiple time points. Pearson correlation tests were used to measure the strength of association between variables.
RESULTS
IFN-α Treatment Decreases Cell-Associated HIV-1 DNA
To investigate the effect of IFN-α on residual reservoirs of HIV-1-infected cells in vivo, we focused on a large cohort of ART-treated HIV-1/HCV-coinfected patients who received weekly treatment with peg-IFN-α in combination with RBV for HCV infection. Demographical and clinical characteristics as well as median duration of HCV therapy are listed in Table 1 . PBMC samples were collected at baseline and after completion of treatment with peg-IFN-α and RBV, and used to assess cell-associated HIV-1 DNA levels in isolated CD4 T cells. We noted reduced absolute and relative CD4 T-cell counts after IFN-α treatment ( Figure 1A ), consistent with recognized hematologic effects of IFN-α treatment. Notably, per-cell levels of HIV-1 DNA copies also decreased during therapy with peg-IFN-α, indicating that HIV-1-infected CD4 T cells are more susceptible to effects of IFN-α than HIV-1-uninfected cells ( Figure 1B ). The total viral reservoir, defined by HIV-1 DNA copies/μL of blood and calculated as a composite marker influenced by absolute changes in CD4 T cells and relative HIV-1 DNA copies per cell, showed most profound reductions during the 2 time points ( Figure 1C) . Notably, the rs12979860 polymorphism in the IL28B gene, known to influence responsiveness to treatment with IFN-α in the context of HCV infection [18] , was not associated with changes in CD4 T-cell counts or cell-associated HIV-1 DNA levels during treatment with peg-IFN-α in our study cohort (Supplementary Figure 1) .
HIV-1-Specific CD8 T Cells Are Unrelated to HIV-1 DNA Changes During IFN-α Treatment
To decipher the mechanism of HIV-1 DNA decrease during IFN-α treatment, we initially analyzed changes in CD8 T cells in our study cohort. We observed that immune activation of total CD8 T cells, determined by surface expression of CD38 and HLA-DR, was not significantly different between pre-and posttreatment time points, except for the CD38 -/HLA-DR + population, which showed a lower frequency after completion of IFN-α therapy (Supplementary Figure 2A) . Notably, the proportion of activated CD38 + /HLA-DR + CD8 T cells was positively associated with HIV-1 DNA levels, supporting the assumption that immune activation is driving persistence of viral reservoir cells (Supplementary Figure 2B) . Intracellular expression of perforin, as well as secretion of IFN-γ, IL-2, and TNF-α in Gag-specific CD8 T cells was assessed in a subset of our patients in whom sufficient cell numbers were available; however, these parameters did not significantly change during treatment with IFN-α and were unrelated to cell-associated HIV-1 DNA levels (Supplementary Figure 2C and 2D ). These Bivariate comparisons between pre-and posttreatment were performed using Wilcoxon matched paired signed-rank tests. **P < .01; ****P < .0001.
results suggest that CD8 T cells are not involved in the reduction of HIV-1 DNA during IFN-α treatment.
NK Cell Frequencies Are Associated With HIV-1 DNA Levels During IFN-α Treatment
We subsequently focused on evaluations of NK cells, the major effector component of the innate immune system, in our study patients. We found that the frequency of total NK cells was not significantly different between pre-and posttreatment ( Figure 2A) ; however, the relative proportions of NK cells from pre-and posttreatment time points were inversely associated with cell-associated HIV-1 DNA levels, suggesting a role of NK cells in influencing proviral reservoirs ( Figure 2D ). Further subcategorization of NK cells according to a previously described classification system [19] ( Figure 2B and 2C Figure 2C ). Interestingly, using a GEE analysis model, we observed that pre-and posttreatment proportions of CD56 bright CD16 -and CD56 bright CD16 + NK cells, the 2 cell populations exhibiting most pronounced changes during IFN-α therapy, were negatively correlated with the corresponding cell-associated HIV-1 DNA ( Figure 2D) ; the strongest negative association was noted for the CD56 bright CD16 + NK cell subset.
Correlations Between Cell-Associated HIV-1 DNA and Phenotypically Complex NK Cell Subsets
Next, we assessed the effect of the IFN-α treatment on the phenotypic profile of NK cells by measuring the surface expression levels of activation markers (CD38, CD57, NKG2D, NKp30, NKp46) markers and immunoregulatory molecules (NKG2A). We observed that IFN-α treatment increased CD38, NKG2A, and NKp30 expression in all or most NK subsets, while increases in NKG2D were restricted to total, CD56 Using a GEE analysis model, we observed that across all NK cell subsets, the frequency of NKG2D-and NKp30-expressing NK cells negatively correlated with the corresponding cellassociated HIV-1 DNA levels ( Figure 3A and 3B) . Proportions of NKp46-expressing NK cell subsets also negatively correlated with the corresponding HIV-1 DNA levels in the total, CD56 Figure 3C ). Notably, there was no association between NK cell activation markers and CD4 T-cell-associated HIV-1 DNA at baseline prior to initiation of treatment with IFN-α. Together, these results suggest that reduction of HIV-1 DNA during treatment with peg-IFN-α might to a considerable extent be attributable to NK cell-mediated elimination of virally infected cells.
DISCUSSION
Viral reservoir cells typically decline within the first 3 years after ART initiation and then persist at a remarkably constant steady-state level. Recent findings suggest that these viral reservoir dynamics are at least partially attributable to latently HIV-1-infected CD4 T cells that stabilize viral reservoir persistence through clonal proliferation [21, 22] . The number of viral reservoirs cells was tightly associated with the kinetics of viral rebound during ART interruptions in several studies [23] [24] [25] [26] , suggesting that reducing the frequency of these cells through pharmacological or immunological interventions would likely translate into more extended periods of time that HIV-1-infected individuals could maintain undetectable viral loads after treatment discontinuation. Yet, many clinical strategies aiming at decreasing the number of viral reservoir cells have failed to induce noticeable reductions of viral reservoir cells in the past. Such efforts included treatment intensification with antiretroviral combination regimens including ≥3 drug classes [27, 28] , the use of passively administered broadly neutralizing antibodies [29] , or studies with pharmacological agents that disrupt viral latency and putatively sensitize infected cells to immune recognition and immune-mediated killing [30, 31] . Notably, unselective killing of CD4 T cells in the context of chemotherapy administered for malignant diseases resulted in expansion of viral reservoir cells instead of limiting the viral reservoir pool, thus highlighting the extreme resistance of viral reservoir cells against eradication efforts [32] . Here, we show that in a relatively large cohort of HIV-1/HCV-coinfected patients, treatment with peg-IFN-α and RBV induced a 2-to 3-fold reduction of per-cell levels of HIV-1 DNA, and diminished total levels of HIV-1 DNA/µL of blood by 3-to 5-fold. While encouraging, it is clear that these effects are far away from the levels of proviral DNA reductions likely to be necessary for allowing clinically meaningful periods of undetectable viremia during ART interruptions [33] . While a general CD4 T-cell decline is well-recognized as a side effect of IFN-α treatment by clinicians, our data clearly show that HIV-1-infected CD4 T cells are eliminated at a higher rate than noninfected cells, implying that HIV-1-infected cells are more susceptible to IFN-α-mediated killing; this is consistent with previous studies in which a selective reduction of HIV-1-infected CD4 T cells was reported during IFN-α therapy [5, 7, 34] . The mechanisms underlying HIV-1 proviral DNA decrease during treatment with IFN-α in this and prior studies are unclear but deserve detailed exploration. By inducing expression of a large number of interferon-stimulated genes, IFN-α can influence a variety of pleiotropic biological processes that affect HIV-1 immune recognition, cell-intrinsic antiviral immune defense mechanisms in CD4 T cells, and innate and adaptive effector cell responses. For instance, recent work has shown that treatment with IFN-α can effectively upregulate expression of several HIV-1 restriction factors known to affect the efficacy of viral pre-and postintegration steps [35, 36] . Among these molecules is RIG-I, an interferon-inducible sensor of viral RNA, that can recognize HIV-1 transcripts and activate intracellular mechanisms contributing to selective death of HIV-1-infected cells [37] . Profiling gene expression changes in CD4 T cells during IFN-α treatment in future studies may allow to identify specific interferon-stimulated host genes in CD4 T cells that are most closely associated with proviral HIV-1 DNA changes.
In addition to these cell-intrinsic mechanisms, it is conceivable that IFN-α can reduce HIV-1-infected cells through activation of HIV-1-specific T cells, which seem to influence the size and composition of viral reservoir cells [38] . Indeed, it is well documented that IFN-α can have an adjuvant effect on cytotoxic T-lymphocyte (CTL) and increase their potency and antiviral efficacy [39, 40] . Yet, in our work, HIV-1-specific CTL were of relatively little magnitude, as frequently observed in ART-treated patients, and there was no statistical association between antiviral cytotoxic T-cell responses and viral reservoirs. Instead, we observed multiple inverse associations between total or phenotypically complex NK cell populations and the residual number of virally infected cells, implying that higher frequencies of NK cell populations were associated with lower per-cell copies of HIV-1 DNA. This observation is consistent with and complements prior studies in which associations between NK cells and proviral reservoirs were reported [41, 42] . Notably, IFN-α can activate NK cell-mediated lysis of HIV-1-infected CD4 + T cells through NKp46-and NKG2D-dependent mechanisms [13] , and both of these markers, along with NKp30, were upregulated during IFN-α therapy and inversely correlated with the HIV-1 reservoir. NKG2A expression was also increased on NK cells during IFN-α treatment; however, its role for NK cell-mediated killing of HIV-1-infected cells is less clear and deserves further investigation. Together, these observations support the hypothesis that activation of NK cells represents a predominant mechanism contributing to HIV-1 proviral reservoir decline during IFN-α treatment.
The data presented here have multiple limitations. First, this is a retrospective evaluation of HIV-1 DNA levels in an uncontrolled study cohort. Moreover, our study subjects received IFN-α for variable durations of time, which may further introduce biases that we cannot correct for with our retrospective analytic approach. Second, we analyzed short fragments of HIV-1 DNA as a biomarker of viral reservoir size, and although being predictive of replication-competent HIV-1 DNA in some studies [43] , it is well recognized that quantification of HIV-1 gag DNA is less informative than analysis of replication-competent virus by outgrowth assays or full-genome viral sequencing, which we were unable to perform in this study due to limitations in PBMCs available from study subjects. It is also important to note that our results differ from previous observations in HIV-1-infected humanized mice, in which inhibition of IFN-α signaling synergized with ART in reducing viral reservoirs [44, 45] . Finally, our studies are limited to analysis of NK and T cells in peripheral blood, although a large number of viral reservoir cells and antiviral immune responses are located in lymphoid tissues.
In conclusion, this study shows substantial reductions of HIV-1 DNA during treatment with IFN-α that were unrelated to HIV-1-specific CD8 T cells but closely connected to NK cell populations, specifically those expressing the activation and cytotoxicity markers NKG2D, NKp30, and NKp46. These data advance our current understanding of how type I interferon responses can influence viral reservoirs, and suggest that IFN-α could represent a valuable component of future viral eradication strategies.
